MURA Key Statistics, Chart & Performance
The current stock price of MURA is 2.04 USD. In the past month the price decreased by -1.92%. In the past year, price decreased by -49.63%.
MURA Technical Analysis
MURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MURA. MURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MURA Financial Highlights
Over the last trailing twelve months MURA reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS increased by 24.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -181.12% | ||
| ROE | -215.81% | ||
| Debt/Equity | 0 |
MURA Forecast & Estimates
6 analysts have analysed MURA and the average price target is 6.12 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 2.04.
MURA Ownership
About MURA
Company Profile
Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. The company is headquartered in Dublin, Dublin and currently employs 116 full-time employees. The company went IPO on 2023-11-03. The firm is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The firm has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
Company Info
MURAL ONCOLOGY PLC
10 Earlsfort Terrace
DUBLIN DUBLIN IE
Employees: 104
Phone: 35319058020
MURAL ONCOLOGY PLC / MURA FAQ
What does MURA do?
Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. The company is headquartered in Dublin, Dublin and currently employs 116 full-time employees. The company went IPO on 2023-11-03. The firm is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The firm has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
Can you provide the latest stock price for MURAL ONCOLOGY PLC?
The current stock price of MURA is 2.04 USD.
What is the dividend status of MURAL ONCOLOGY PLC?
MURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MURA stock?
MURA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the ownership details for MURA stock?
You can find the ownership structure of MURAL ONCOLOGY PLC (MURA) on the Ownership tab.